Literature DB >> 25733682

The control operated by the cell cycle machinery on MEF2 stability contributes to the downregulation of CDKN1A and entry into S phase.

Eros Di Giorgio1, Enrico Gagliostro1, Andrea Clocchiatti1, Claudio Brancolini2.   

Abstract

MEF2s are pleiotropic transcription factors (TFs) which supervise multiple cellular activities. During the cell cycle, MEF2s are activated at the G0/G1 transition to orchestrate the expression of the immediate early genes in response to growth factor stimulation. Here we show that, in human and murine fibroblasts, MEF2 activities are downregulated during late G1. MEF2C and MEF2D interact with the E3 ligase F-box protein SKP2, which mediates their subsequent degradation through the ubiquitin-proteasome system. The cyclin-dependent kinase 4 (CDK4)/cyclin D1 complex phosphorylates MEF2D on serine residues 98 and 110, and phosphorylation of these residues is an important determinant for SKP2 binding. Unscheduled MEF2 transcription during the cell cycle reduces cell proliferation, whereas its containment sustains DNA replication. The CDK inhibitor p21/CDKN1A gene is a MEF2 target gene required to exert this antiproliferative influence. MEF2C and MEF2D bind a region within the first intron of CDKN1A, presenting epigenetic markers of open chromatin. Importantly, H3K27 acetylation within this regulative region depends on the presence of MEF2D. We propose that following the initial engagement in the G0/G1 transition, MEF2C and MEF2D must be polyubiquitylated and degraded during G1 progression to diminish the transcription of the CDKN1A gene, thus favoring entry into S phase.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25733682      PMCID: PMC4387215          DOI: 10.1128/MCB.01461-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  Control of cardiac-specific transcription by p300 through myocyte enhancer factor-2D.

Authors:  T I Slepak; K A Webster; J Zang; H Prentice; A O'Dowd; M N Hicks; N H Bishopric
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

2.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

3.  Regulatory role of MEF2D in serum induction of the c-jun promoter.

Authors:  T H Han; R Prywes
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

4.  Krüppel-like factor 4 (gut-enriched Krüppel-like factor) inhibits cell proliferation by blocking G1/S progression of the cell cycle.

Authors:  X Chen; D C Johns; D E Geiman; E Marban; D T Dang; G Hamlin; R Sun; V W Yang
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

5.  Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis.

Authors:  Gabriela Paroni; Michela Mizzau; Clare Henderson; Giannino Del Sal; Claudio Schneider; Claudio Brancolini
Journal:  Mol Biol Cell       Date:  2004-04-09       Impact factor: 4.138

6.  hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors.

Authors:  J C McDermott; M C Cardoso; Y T Yu; V Andres; D Leifer; D Krainc; S A Lipton; B Nadal-Ginard
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

7.  Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21.

Authors:  Y Li; C W Jenkins; M A Nichols; Y Xiong
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

8.  KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1.

Authors:  Jinghai Wu; Jerry B Lingrel
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

9.  Requirement of MEF2A, C, and D for skeletal muscle regeneration.

Authors:  Ning Liu; Benjamin R Nelson; Svetlana Bezprozvannaya; John M Shelton; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

10.  A novel complex regulates cardiac actin gene expression through interaction of Emb, a class VI POU domain protein, MEF2D, and the histone transacetylase p300.

Authors:  S Molinari; F Relaix; M Lemonnier; B Kirschbaum; B Schäfer; M Buckingham
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

View more
  23 in total

1.  Dysregulated mitogen-activated protein kinase pathway mediated cell cycle disruption in sporadic parathyroid tumors.

Authors:  A K Arya; P Singh; U N Saikia; N Sachdeva; D Dahiya; A Behera; S D Rao; S K Bhadada
Journal:  J Endocrinol Invest       Date:  2019-09-18       Impact factor: 4.256

2.  Transformation by different oncogenes relies on specific metabolic adaptations.

Authors:  Paolo Peruzzo; Marina Comelli; Eros Di Giorgio; Elisa Franforte; Irene Mavelli; Claudio Brancolini
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

Review 3.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

4.  MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

Authors:  Fiona C Brown; Eric Still; Richard P Koche; Christina Y Yim; Sumiko Takao; Paolo Cifani; Casie Reed; Shehana Gunasekera; Scott B Ficarro; Peter Romanienko; Willie Mark; Craig McCarthy; Elisa de Stanchina; Mithat Gonen; Venkatraman Seshan; Patrick Bhola; Conor O'Donnell; Barbara Spitzer; Crystal Stutzke; Vincent-Philippe Lavallée; Josée Hébert; Andrei V Krivtsov; Ari Melnick; Elisabeth M Paietta; Martin S Tallman; Anthony Letai; Guy Sauvageau; Gayle Pouliot; Ross Levine; Jarrod A Marto; Scott A Armstrong; Alex Kentsis
Journal:  Cancer Discov       Date:  2018-02-05       Impact factor: 39.397

5.  A population of G2-arrested cells are selected as sensory organ precursors for the interommatidial bristles of the Drosophila eye.

Authors:  Joy H Meserve; Robert J Duronio
Journal:  Dev Biol       Date:  2017-06-21       Impact factor: 3.582

6.  Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription.

Authors:  Martina Minisini; Eros Di Giorgio; Emanuela Kerschbamer; Emiliano Dalla; Massimo Faggiani; Elisa Franforte; Franz-Josef Meyer-Almes; Rino Ragno; Lorenzo Antonini; Antonello Mai; Francesco Fiorentino; Dante Rotili; Monica Chinellato; Stefano Perin; Laura Cendron; Christian X Weichenberger; Alessandro Angelini; Claudio Brancolini
Journal:  Nucleic Acids Res       Date:  2022-03-21       Impact factor: 16.971

7.  MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity.

Authors:  Eros Di Giorgio; Liqing Wang; Yan Xiong; Tatiana Akimova; Lanette M Christensen; Rongxiang Han; Arabinda Samanta; Matteo Trevisanut; Tricia R Bhatti; Ulf H Beier; Wayne W Hancock
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

8.  HDAC4 degradation during senescence unleashes an epigenetic program driven by AP-1/p300 at selected enhancers and super-enhancers.

Authors:  Eros Di Giorgio; Harikrishnareddy Paluvai; Emiliano Dalla; Liliana Ranzino; Alessandra Renzini; Viviana Moresi; Martina Minisini; Raffaella Picco; Claudio Brancolini
Journal:  Genome Biol       Date:  2021-05-10       Impact factor: 13.583

Review 9.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

10.  A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells.

Authors:  Eros Di Giorgio; Liqing Wang; Yan Xiong; Lanette M Christensen; Tatiana Akimova; Rongxiang Han; Arabinda Samanta; Matteo Trevisanut; Claudio Brancolini; Ulf H Beier; Wayne W Hancock
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.